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Background: The reported efficacy of memantine in the treatment of patients with cluster headache (CH) suggests
that NMDA receptors are involved in mechanisms of nociceptive sensitization within the trigeminal system associated
with CH. NMDA receptors are activated or inhibited by neuroactive compounds generated by tryptophan metabolism
through the kynurenine pathway. In the accompanying manuscript, we have found that serum levels of all kynurenine
metabolites are altered in patients with chronic migraine. Here, we have extended the study to patients affected by
episodic or chronic CH as compared to healthy controls.
Method: We assessed serum levels of kynurenine (KYN), kynurenic Acid (KYNA), anthranilic acid (ANA), 3-hydroxy-
anthranilic acid (3-HANA), 3-hydroxykynurenine (3-HK), xanthurenic acid (XA), quinolinic acid (QUINA), tryptophan (Trp)
and 5-hydroxyindolacetic acid (5-HIAA) by means of a liquid chromatography/tandem mass spectrometry (LC/MS-MS)
method in 21 patients affected by CH (15 with episodic and 6 with chronic CH), and 35 age-matched healthy subjects.
Patients with psychiatric co-morbidities, systemic inflammatory, endocrine or neurological disorders, and mental
retardation were excluded.
Results: LC/MS-MS analysis of kynurenine metabolites showed significant reductions in the levels of KYN
(-36 %), KYNA (-34 %), 3-HK (-51 %), 3-HANA (-54 %), XA (-25 %), 5-HIAA (-39 %) and QUINA (-43 %) in the
serum of the overall population of patients affected by CH, as compared to healthy controls. Serum levels of
Trp and ANA were instead significantly increased in CH patients (+18 % and +54 %, respectively). There was
no difference in levels of any metabolite between patients affected by episodic and chronic CH, with the
exception of KYN levels, which were higher in patients with chronic CH.
Conclusion: The reduced levels of KYNA (an NMDA receptor antagonist) support the hypothesis that NMDA
receptors are overactive in CH. A similar reduction in KYNA levels was shown in the accompanying manuscript in
patients affected by chronic migraine. The reduced levels of XA, a putative analgesic compound, may contribute
to explain the severity of pain attacks in CH. These data, associated with the data reported in the accompanying
manuscript, supports a role for the kynurenine pathway in the pathophysiology of chronic headache disorders.
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Cluster headache (CH), the most frequent primary head-
ache disorder among the trigeminal autonomic cephalal-
gias, can be chronic or episodic depending on the
presence of remission periods between the headache
bouts [1–5]. The molecular events underlying the patho-
physiology of CH are unknown because of the lack of
valuable experimental animal model, and, therefore the
treatment is largely based on empirical evidence [6]. It is
intuitive that the hypothalamus and the trigeminal sys-
tem are involved in the pathophysiology of CH. The
involvement of the hypothalamus is suggested by the
circannual and circadian periodicity of headache and by
the prevalence of CH in males. In addition, changes in
the secretion of hormones regulated by the hypothal-
amus, such as prolactin, growth hormone and cortisol
are found in patients affected by CH [7–9], and func-
tional imaging studies showed the activation of hypo-
thalamic gray matter during headache attacks [6, 10].
Headache pain of CH is conveyed to the CNS via the
ophthalmic branch of the trigeminal system, and, simi-
larly to migraine, activation of the trigeminovascular sys-
tem has been demonstrated during CH attacks [11].
Mechanisms of nociceptive sensitization developing at the
synapses between primary afferent fibers and secondary
order neurons of the caudal trigeminal nucleus, and in
upper regions of the pain neuraxis likely contribute to the
development of the typical unilateral attacks of pain asso-
ciated with CH. Glutamate acting at N-methyl-D-aspar-
tate (NMDA) receptors plays a key role in the induction
of nociceptive sensitization [12], and this suggests that
alterations in NMDA receptor signaling or in the en-
dogenous machinery that activates NMDA receptors may
be relevant to the pathophysiology of CH. It is consistent
with this hypothesis that memantine, a fast off-rate
NMDA-gated ion channel blocker, has shown efficacy in
reducing CH attacks in resistant patients, even if clinical
studies are still limited [13].
The kynurenine pathway of tryptophan metabolism
generates neuroactive metabolites that influence the
activity of NMDA receptors as well as other glutamate
receptor types [14, 15]. In this pathway, L-tryptophan is
first metabolized into N-formyl-kynurenine, which is then
converted into L-kynurenine (KYN). KYN is then transami-
nated into KYNA by kynurenine aminotransferases (KATs),
or, alternatively, converted into 3-hydroxykynurenine (3-
HK) by kynurenine monoxygenase or transformed into
anthranilic acid (ANA) by kynureninase. 3-HK is the pre-
cursor of 3-hydroxyanthranilic acid (3-HANA), quinolinic
acid (QUINA), and xanthurenic acid (XA) (reviwed by
Schwarcz et al. 2012) [16]. QUINA is an NMDA receptor
agonist, whereas KYNA blocks the action of the co-agonist,
glycine, at the GluN1 subunit of NMDA receptors
(reviewed by Schwarcz et al. 2012) [16]. XA activatesmGlu2 and mGlu3 metabotropic glutamate receptors, al-
though its precise mechanism of action is unknown [17]. In
the accompanying manuscript we showed for the first time
that chronic migraine is associated with alterations in
serum levels of kynurenine metabolites, which are in line
with the hypothesis of a hyperactivity of NMDA receptors
in migraine. Since hyperactive NMDA receptors play a role
in nociceptive sensitization, we hypothesized that kynure-
nine glutamatergic metabolites might be altered in CH and
extended the analysis to patients affected by episodic or
chronic CH as compared to age-matched healthy controls.
Methods
Patients
The protocol was carried out in accordance with the
declaration of Helsinki and the study design was
reviewed and approved by the Ethical Committee at
Sapienza, University of Rome, Sant’Andrea Hospital. All
subjects signed free informed consent for participation
in the study. All subjects were enrolled by the Regional
Referral Headache Center of S. Andrea Hospital and
evaluated by two experts in headache disorders (A.N.
and P.M.). 21 patients met the ICHD-3beta criteria [1]
for cluster headache, chronic or episodic, and were
included in the CH group and 35 healthy volunteers,
recruited among the Hospital and University employees,
were included in the age-matched control group. Inclu-
sion criteria for CH patients were: (i) age between 18
and 65 years; (ii) patients affected by CH during the
active phase (ICHD-3beta criteria) [1]; (iii) patients
treated with verapamil (120–480 mg) for prophylactic
therapy and sumatriptan (oral 50 mg, subcutaneous
6 mg) as the acute pain medication.
Exclusion criteria for both patients and controls were:
(i) the presence of psychiatric co-morbidities, systemic
inflammatory disorders, endocrine disorders, neuro-
logical disorders, and mental retardation; (ii) lifetime
history of cluster headache (for healthy volunteers); and
(iii) the use of any drug of abuse in the last 3 months
(except cigarette smoking).
A detailed medical anamnesis was obtained from pa-
tients and controls, and the daily frequency of cluster
headache attacks was recorded for each patient. Patients
were sampled during the CH active phase, independently
of the presence of an ongoing attack. Sumatriptan intake
was allowed until 12 h before the blood sample.
Blood collection and KP measurement
Serum samples from patients and controls with empty
stomach were collected between 10 am and 12 am. Blood
(5 ml) was sampled in anticoagulant-free tubes and kept
at room temperature for 1 h before the serum was isolated
(centrifugation at 2000 g for 10 min at 20 °C). Aliquots of
serum were stored at -80 °C until analysis.
Table 1 Demographic and clinical characteristics and serum




CH (n = 21)
χ2/U p
Gender (M, %) 27 (77.1) 19 (90.5) 1.59
0.19
Age (years; mean ± SD) 44.8 ± 7.64 44,4 ± 7.60 278
0.13
Chronic cluster headache (n, %) – 6 (28.6 %) –
Mean daily frequency of
attacks (mean ± SD)
– 2.05 ± 0.86 –
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dem mass spectrometry (LC/MS-MS) method for the
assay of serum levels of all kynurenine metabolites.
The method allowed a reliable detection of KYN,
KYNA, ANA, 3-HANA, 3- HK, XA, and QUINA.
Levels of tryptophan (Trp) and 5-hydroxyindolacetic
acid (5-HIAA) were also detected. Details on sample
preparation, reagents, standard solutions, chromato-
graphic conditions, mass spectrometry conditions, and
validation parameters are reported in Tables S1-S3 of
Fazio et al. 2015 [17].Trp (μg/ml) (mean ± SD) 5.50 ± 1.71 6.50 ± 1.60 233
0.01
KYN (μg/ml) (mean ± SD) 0.36 ± 0.15 0.23 ± 0.11 165.5
<0.01
KYNA (ng/ml) (mean ± SD) 3.15 ± 1.39 2.09 ± 1.49 189
0.03
ANA (ng/ml) (mean ± SD) 1.85 ± 1.57 2.85 ± 1.37 199
<0.01
3-HK (ng/ml) (mean ± SD) 2.16 ± 1.58 1.05 ± 0.84 217
0.01
3-HANA (ng/ml) (mean ± SD) 9.76 ± 4.38 4.50 ± 1.52 67.5
<0. 01
QUINA (ng/ml) (mean ± SD) 16.3 ± 10.1 9.28 ± 2.28 115
<0.01Statistical analysis
SPSS version 19.00 (IBM Corporation, Armonk NY,
USA) was used for data analysis. Continuous variables
were expressed as mean standard ± deviation (S.D.),
while discrete variables were assigned as numbers and
percentages. The compliance of continuous variables
with normal distribution was controlled with the Kolmo-
gorov–Smirnov test. Whether Healthy Controls and
Cluster Headache groups differed in terms of discrete
variables was checked through Pearson’s Chi Squared
test (χ2). Since continuous variables did not comply with
a normal distribution, the Mann–Whitney U test was
used for between group comparisons. Spearman’s Rho
correlation (ρ) was used to test between-variables rela-
tionships. We set statistical significance at P ≤ 0.05.5-HIAA (ng/ml) (mean ± SD) 33.4 ± 13.7 20.5 ± 8.36 156.5
<0.01
XA (ng/ml) (mean ± SD) 1.77 ± 0.95 1.32 ± 1.53 148
0.02Results
Patients characteristics and serum levels of kynurenine
metabolites
Demographic and clinical features of patients affected by
CH (n = 21) and age-matched healthy controls (n = 35)
are shown in Table 1. The CH group, as expected,
showed a prevalence of male gender (90.5 %), which
was not significantly higher than in the group of se-
lected HCs (77.1 %). Mean age was similar between
the two groups (about 44 years) and mean frequency
of headache attacks in CH patients was about 2 at-
tacks/day. Six patients were affected by chronic CH,
and the remaining 15 patients were affected by epi-
sodic CH. The latter patients were examined during
the active phase of CH.
LC/MS-MS analysis of kynurenine metabolites
showed significant reductions in serum levels of KYN
(-36 %), KYNA (-34 %), 3-HK (-51 %), 3-HANA
(-54 %), XA (-25 %), 5-HIAA (-39 %) and QUINA
(-43 %) in the serum of the overall population of
patients affected by CH, as compared to HCs (Table 1,
Fig. 1). Serum levels of Trp and ANA were instead
significantly increased in patients affected by CH
(+18 % and +54 %, respectively).Kynurenine metabolites levels in the serum of patients
with chronic and episodic CH, and correlations with daily
headache frequency
Analysis of serum levels of kynurenine metabolites in
patients affected by episodic or chronic CH showed no
differences between the two subgroups, with exception
of KYN levels, which were significantly higher (+50 %)
in patients affected by chronic CH (Table 2).
No significant correlations were found between any
kynurenine metabolite and daily frequency of headache
attacks (not shown).
Discussion
The profile of serum kynurenine metabolites in patients
affected by CH was similar to that reported in the ac-
companying manuscript in patients with chronic mi-
graine with two notable exceptions: (i) XA levels, which
were decreased in patients with CH, but increased in
patients with chronic migraine; and, (ii) ANA levels,





Fig. 1 Percent changes in serum kynurenine metabolites in patients affected by CH with respect to healthy controls. Data are presented as per
cent of HC values for each metabolite. Values are means ± S.E.M. *p < 0.05 vs. healthy controls (HCs)
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have highlighted in the accompanying manuscript,
serum levels of kynurenine metabolites may roughly
mirror CNS levels because the constitutive action of the
kynurenine pathway is low in the CNS, and at least KYN
and 3-HK of peripheral source can cross the blood-brain
barrier and fuel the pathway in the brain parenchyma
[16]. The most relevant finding here is the reduction in
KYNA levels, which, within the context of an enhanced
release of glutamate might contribute to a hyperactivity of
NMDA receptors resulting into nociceptive sensitization
in CH. Thus, the reductions in KYNA levels found in
patients affected by CH (present data) and in patients
affected by chronic migraine (see accompanying manu-
script) represent a nice clinical counterpart of the numer-
ous experimental data that demonstrate the ability of
KYNA to restrain the activation of the trigeminal system
[18–22]. In fact, several preclinical studies demonstrated
the mediatory and modulatory role of KYNA for glutam-
ate and its receptors in central and peripheral painprocessing [23]. Some of the identified roles are: the
attenuation of the cutaneous nociceptors sensitization by
the inactivation of peripheral glutamate receptors [24], the
probable reduction of the first-order neurons activation
and of the consecutive release of CGRP and nitric oxide
from the nerve endings in the trigeminal nucleus caudalis
[22] and the inhibition of the neural activity on brain stem
structures such as the locus coeruleus, periaqueductal grey
and nucleus raphe magnus [25–28].
The different behavior of XA in patients by CH and
chronic migraine is interesting and deserves some com-
ments. XA is a putative neurotransmitter [29] that activates
mGlu2 and mGlu3 metabotropic glutamate receptors [17],
and may also indirectly influence glutamatergic transmis-
sion by interacting with vesicular glutamate transporters
[30]. Activation of mGlu2 receptors causes analgesia by
negatively modulating glutamate release from primary
afferent fibers [31], and preliminary data demonstrate the
analgesic activity of XA in rodents (M. Bernabucci and F.
Fazio, unpublished observation). Hence, the increase in
Table 2 Kynurenine pathway metabolites in Chronic and






Trp (μg/ml) (mean ± SD) 6.60 ± 1.74 6.57 ± 1.32 43.5
0.91
KYN (μg/ml) (mean ± SD) 0.20 ± 0.07 0.31 ± 0.16 20.0
0.05
KYNA (ng/ml) (mean ± SD) 1.91 ± 1.43 2.52 ± 1.67 34.0
0.42
ANA (ng/ml) (mean ± SD) 2.67 ± 1.44 3.30 ± 1.18 30.0
0.27
3-HK (ng/ml) (mean ± SD) 1.21 ± 0.94 0.66 ± 0.29 30.5
0.27
3-HANA (ng/ml) (mean ± SD) 4.44 ± 1.69 4.22 ± 1.11 42.0
0.85
QUINA (ng/ml) (mean ± SD) 9.33 ± 2.36 8.54 ± 2.17 7.00
0.93
5-HIAA (ng/ml) (mean ± SD) 18.4 ± 6.32 25.8 ± 10.9 21.0
0.07
XA (ng/ml) (mean ± SD) 1.33 ± 1.59 1.18 ± 1.07 6.00
0.93
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graine has been interpreted as a defensive mechanism
aimed at reducing the extent of headache in migraine.
This potential defense was absent in patients with
CH, where serum XA levels were reduced. We specu-
late on the possibility that a reduced production of
XA contributes to the severity of pain attacks in CH,
and that pharmacological strategies aimed at enhan-
cing XA biosynthesis or reducing XA catabolism
might cause analgesia in CH patients. This attractive
hypothesis warrants further investigation. ANA levels
were found to be increased in patients affected by
both CH and chronic migraine, suggesting that, in
both disorders, KYN is preferentially metabolized by
kynureninase rather than by kynurenine monoxygen-
ase or kynurenine aminotransferases (see also accom-
panying manuscript). Why ANA levels were much
more elevated in chronic migraine than in CH is un-
known. The only biochemical explanation is that
ANA transformation into 3-HANA or other catabo-
lites is dramatically reduced in chronic migraine, but
not in CH. The incomplete knowledge of the metabolism
of ANA makes this hypothesis difficult to prove. The
marked difference in ANA levels between chronic
migraine and CH suggests that this compound may serve
as a peripheral biomarker that may facilitate the correct
diagnosis of patients with chronic headache with mixed
clinical features.Alterations of serum kynurenine pathway metabolites
have been found in other neuropsychiatric disorders
[16], have been linked to chronic stress [32] and sleep
deprivation [33]. Although we did not recruit patients
affected by psychiatric comorbidities, we cannot exclude
that the chronic stress associated to the active CH con-
dition, often associated with sleep disturbances, might
have affected tryptophan metabolism.
Conclusion
In conclusion, we have shown for the first time that CH
is associated with abnormalities of the kynurenine path-
way of tryptophan metabolism, as reflected by substan-
tial alterations of all kynurenine metabolites in the
peripheral blood. This manuscript and the accompany-
ing manuscript reporting data obtained in patients with
chronic migraine are in line with the increasing number
of preclinical data that highlight the importance of the
kynurenine pathway in the pathophysiology and treat-
ment of chronic headache disorders.
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